Rapid Multiplexing with Opal® Research Kits Now Available on LabSat™ Platform
23.5.2019 13:30:00 EEST | Business Wire | Press release
Lunaphore Technologies S.A., a Swiss medtech firm developing innovative next-generation equipment for cancer research and tissue diagnostics, announces a new rapid multiplexing application for its LabSat™ Research instrument.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190523005082/en/
FFPE IF of tonsil, 6-plex + DAPI. Total staining time: 4h12 (with Opal® 7-Color Manual IHC Kit) (Photo: Business Wire)
Following the signature of a co-marketing agreement between Lunaphore Technologies S.A. and Akoya Biosciences, Inc.; Lunaphore will start providing multiplexing protocols using Akoya’s Opal® immunoassay kits for its staining platform LabSat™ Research, Lunaphore’s first solution to reach the market.
LabSat™ is shown to perform rapid tests on tissue samples under 2.5 hours for a 3-plex plus counterstaining with the Opal® 4-Color Manual IHC Kit; and under 4.5 hours for a 6-plex plus counterstaining with the Opal® 7-Color Manual IHC Kit1. These timeframes present a 3 to 4-fold time improvement compared to the current turnaround times for Opal® 7-Color kit using manual protocols or other automation standards. During the study conducted by both companies, comparable intensity to other staining methods was observed, while reproducibility presented less than 20% of variability1. Moreover, uniformity throughout the tissue section was tested with excellent results, obtaining a signal gradient under 10% over 1 cm of tissue1. This opens opportunities for users to analyze images and quantify signals using Akoya’s imaging and software tools.
These short turnaround times are achieved thanks to a novel microfluidic tissue processor lying at the core of Lunaphore’s innovation, which allows researchers to perform rapid cycles of optimization in order to reach and repeat the desired multiplexed stainings, without the need to invest in traditional workflow automation instruments.
Lunaphore’s co-founder and CTO, Diego G. Dupouy, said: ”The great stainings obtained with our platform are the result of team effort by Lunaphore and Akoya, as we push both of our technologies to the next level. Our goal is to combine short turnaround times with high-quality stainings in order to enable researchers to develop their own immunophenotyping panels in unprecedented times.”
With the arrival of ultra-rapid automated multiplexing in LabSat™, Lunaphore brings together state-of-the-art multiplexing techniques, the high reproducibility of automation systems and an unmatched speed performance, now at the reach of medium and small laboratories.
About Lunaphore
Lunaphore Technologies S.A. is a Swiss company developing next generation tissue autostainers. The award-winning technology based on microfluidics is called FFeX (Fast Fluidic Exchange). It aims to perform assays much faster than standard techniques and has demonstrated good results in tests with cancer patient samples. Lunaphore was founded in 2014 with the vision of bringing –omics like approaches to tissue diagnostics and has been recognized as one of the most innovative companies nationally and internationally.
About LabSat™ Research
LabSat™ Research is a single-slide, ultra-rapid reagent delivery system performing IHC/IF tests on tissue samples for Research Use Only. The breakthrough speed performance of the device is achieved thanks to a novel microfluidic tissue processor lying at the core of Lunaphore’s innovation. This patented technology enables high precision tissue staining, with a drastic reduction of reagent incubation times.
About IHC/IF and multiplexing
Immunohistochemistry (IHC) staining is a technique that involves the use of antibodies to detect the presence of specific cancer biomarkers on a tissue sample. During an IHC test, the tissue is stained with labelled antibodies, producing a coloring on the tissue that is observable with a bright-field microscope. This coloring or staining will signal the presence and localization of specific cancer biomarkers within the tissue. Immunofluorescence (IF) is a similar technique which instead produces fluorescent stainings observable with a fluorescence microscope. IHC and IF are among the most common tests in immuno-oncology research to support scientists in the identification of specific cancer types.
In order to analyze the tumor microenvironment, understanding the spatial organization and co-expression of multiple biomarkers in a tissue section is of key importance. With this purpose, it is possible to stain and visualize several targets simultaneously with a technique known as multiplexed IHC or IF. With Akoya’s Opal® fluorescent kits -4-color and 7-color- 3 and 6 biomarkers, respectively, can be stained at once in order to maximize the obtention of information from each tissue section.
Disclaimer: LabSat™ Research is approved for Research Use Only and not available for diagnostic procedures. Only marketed in Europe.
1 Data on file.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190523005082/en/
Contact information
Irene Tamayo
Lunaphore Corporate Communications
Email: communications@lunaphore.com
Phone:
+41 21 353 58 22
Andrea Büchler
Lunaphore Finance and Business Development
Email:
andrea.buechler@lunaphore.com
Phone
+41 79 598 40 73
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways to Participate in 2026 Cantor Global Healthcare Conference on September 9, 20261.9.2026 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the 2026 Cantor Global Healthcare Conference on September 9, 2026 and will participate in a fireside chat at 3:20pm ET and a panel entitled “PSYCH! Accessing The New Wave of Psychedelics” at 4:30pm ET. A live audio webcast of the fireside chat will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways We believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. Our initial focus is developing COMP360 psilocybin, a proprietary, investigational, synthetic psilocybin treatment under evaluation for treatment-resis
ChargePoint Accelerates European Growth Strategy with Appointment of John Saffrett as EVP and Managing Director, Europe1.9.2026 12:00:00 EEST | Press release
ChargePoint (NYSE: CHPT), a global leader in intelligent electrification and e-mobility, today announced the appointment of John Saffrett as Executive Vice President and Managing Director, Europe. In this role, Saffrett will be responsible for driving ChargePoint's growth strategy across European markets, overseeing sales, customer relationships, partnerships, and market expansion across the continent. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260901888806/en/ ChargePoint's EVP and Managing Director John Saffrett He has served as a member of the company’s Advisory Council since March 2026 and is a seasoned global mobility executive with more than 25 years of leadership experience across the automotive, fleet management, and financial services industries. As ChargePoint’s new EVP and MD, Europe, he will report directly to CEO Rick Wilmer. “Europe is at the center of our growth ambitions, and John is the ideal leader to a
EMVCo Requests Feedback on Framework for Secure, Interoperable and Scalable Card-Based Agentic Payments1.9.2026 12:00:00 EEST | Press release
EMVCo – the technical body that creates and manages EMV® Specifications and programmes – has released a draft framework to help promote secure, interoperable and scalable card-based agentic payments. The framework provides a foundation for further industry engagement and potential specification development, with all interested stakeholders encouraged to provide their feedback on EMV® Agentic Payments – Framework for Specificationsby Wednesday 30 September. A key focus across the agentic commerce ecosystem is how to establish intent and determine that a consumer delegated authority to an AI agent to make a purchase on their behalf. Following industry input, EMVCo has focused on card-based agentic payment scenarios where intent needs to be managed over time, such as recurring purchases, cumulative budgets and post-transaction activities. These scenarios may require access to a shared intent ‘state’ that persists across multiple participants and their interactions. EMVCo has identified an
Club Vita Launches German VitaCurves Model as Pension Risk Transfer Market Gathers Momentum1.9.2026 11:00:00 EEST | Press release
Club Vita, an international leader in longevity data analytics, has launched a German calibration of its popular address-based longevity model, VitaCurves, further expanding its international footprint and supporting the growing pension risk transfer (PRT) market in Germany. The launch marks another milestone in Club Vita's international expansion and extends its suite of address-based mortality models, which already provides mortality insights in the UK, United States, Canada and the Netherlands. The German VitaCurvesDEU model is already being used by a leading insurer, helping to provide a more granular understanding of longevity risk across pension and insurance portfolios. VitaCurves uses granular location-based and socio-economic data to identify differences in mortality patterns between sub-populations, enabling insurers, pension funds and other stakeholders to develop more accurate longevity assumptions and risk assessments. It also offers a convenient way of anonymizing pension
JEOL: Launch of the New Benchtop Scanning Electron Microscope “JCM-7000Plus NeoScope™”1.9.2026 10:30:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the benchtop scanning electron microscope (SEM) “JCM-7000Plus” and will begin sales on September 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260825564112/en/ JCM-7000Plus NeoScope™ [Development Background] Benchtop scanning electron microscopes are increasingly used in fields including electrical and electronics, automotive and machinery, steel and metals, chemical and pharmaceuticals. They are utilized not only in research and development but also in manufacturing-related applications, such as quality control and product inspection. In addition, they are adopted in educational settings at middle and high schools as well as universities. Given these diverse applications, there is growing demand for improved operational efficiency, simpler and more automated operation, and enhanced observation, analysis, and measurement performance. To meet these needs, we have e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom